| 1. |
- Sun, Xiaoming, et al.
(författare)
-
Adjustable hardness of hydrogel for promoting vascularization and maintaining sternness of stem cells in skin flap regeneration
- 2018
-
Ingår i: Applied Materials Today. - : Elsevier. - 2352-9407. ; 13, s. 54-63
-
Tidskriftsartikel (refereegranskat)abstract
- The matrix mechanical stiffness of biomaterials plays an important role in the pluripotency and biological function of stem cells in the microenvironment. It is a key step to adjust the stiffness of biomaterials for inducing stem cells to promote vascularization in order to promote damaged tissue repair. In this study, we transplant adipose derived stem cells (ADSCs) within an in situ forming dextran hydrogel with controllable mechanical strength formed by cross-linking glycidyl methacrylate derivatized dextran and dithiothreitol, which can regulate the stemness and biological functions of stem cells. We show that softer dextran hydrogel can better maintain stemness markers expression of ADSCs, and significantly stimulate ADSCs to secrete angiogenic factors. The ADSCs-encapsulated hydrogel distinctly promote the skin flap survival compared to direct cell injection. Bioluminescence imaging analysis shows that in situ forming dextran hydrogel can improve cells retention, and postmortem analysis reveals that the transplanted ADSCs with hydrogel can promote vascularization. These results support the use of injectable dextran hydrogel for skin ischemia tissue regeneration. (C) 2018 Elsevier Ltd. All rights reserved.
|
|
| 2. |
- Bruinsma, Sophie M, et al.
(författare)
-
The Movember Foundation's GAP3 cohort : a profile of the largest global prostate cancer active surveillance database to date
- 2018
-
Ingår i: BJU International. - : Wiley. - 1464-4096. ; 121:5, s. 737-744
-
Tidskriftsartikel (refereegranskat)abstract
- OBJECTIVES: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low-risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow-up for AS in this unique global AS database.PATIENTS AND METHODS: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwide (USA, Canada, Australasia, UK and Europe). Data on a total of 15 101 patients were included. Descriptive statistics were used to report patients' clinical and demographic characteristics at the time of PCa diagnosis, clinical follow-up, discontinuation of AS and subsequent treatment. Cumulative incidence curves were used to report discontinuation rates over time.RESULTS: At diagnosis, the median (interquartile range [IQR]) patient age was 65 (60-70) years and the median prostate-specific antigen level was 5.4 (4.0-7.3) ng/mL. Most patients had clinical stage T1 disease (71.8%), a biopsy Gleason score of 6 (88.8%) and one tumour-positive biopsy core (60.3%). Patients on AS had a median follow-up time of 2.2 (1.0-5.0) years. After 5, 10 and 15 years of follow-up, respectively, 58%, 39% and 23% of patients were still on AS. The current version of GAP3 has limited data on magnetic resonance imaging (MRI), quality of life and genomic testing.CONCLUSIONS: GAP3 is the largest worldwide collaboration integrating patient data from men with PCa on AS. The results will allow individual patients and clinicians to have greater confidence in the personalized decision to either delay or proceed with active treatment. Longer follow-up and the evaluation of MRI, new genomic markers and patient-related outcomes will result in even more valuable data and eventually in better patient outcomes.
|
|
| 3. |
- DeWitt, Douglas S., et al.
(författare)
-
Pre-clinical testing of therapies for traumatic brain injury
- 2018
-
Ingår i: Journal of Neurotrauma. - : Mary Ann Liebert. - 0897-7151 .- 1557-9042. ; 35:23, s. 2737-2754
-
Tidskriftsartikel (refereegranskat)abstract
- Despite the large number of promising neuroprotective agents identified in experimental traumatic brain injury (TBI) studies, none has yet shown meaningful improvements in long-term outcome in clinical trials. To develop recommendations and guidelines for pre-clinical testing of pharmacological or biological therapies for TBI, the Moody Project for Translational Traumatic Brain Injury Research hosted a symposium attended by investigators with extensive experience in pre-clinical TBI testing. The symposium participants discussed issues related to pre-clinical TBI testing including experimental models, therapy and outcome selection, study design, data analysis, and dissemination. Consensus recommendations included the creation of a manual of standard operating procedures with sufficiently detailed descriptions of modeling and outcome measurement procedures to permit replication. The importance of the selection of clinically relevant outcome variables, especially related to behavior testing, was noted. Considering the heterogeneous nature of human TBI, evidence of therapeutic efficacy in multiple, diverse (e.g., diffuse vs. focused) rodent models and a species with a gyrencephalic brain prior to clinical testing was encouraged. Basing drug doses, times, and routes of administration on pharmacokinetic and pharmacodynamic data in the test species was recommended. Symposium participants agreed that the publication of negative results would reduce costly and unnecessary duplication of unsuccessful experiments. Although some of the recommendations are more relevant to multi-center, multi-investigator collaborations, most are applicable to pre-clinical therapy testing in general. The goal of these consensus guidelines is to increase the likelihood that therapies that improve outcomes in pre-clinical studies will also improve outcomes in TBI patients.
|
|
| 4. |
- Wang, Yaling, et al.
(författare)
-
Enhanced performance and stability of inverted planar perovskite solar cells by incorporating 1,6-diaminohexane dihydrochloride additive
- 2018
-
Ingår i: Solar Energy Materials and Solar Cells. - : ELSEVIER SCIENCE BV. - 0927-0248 .- 1879-3398. ; 188, s. 140-148
-
Tidskriftsartikel (refereegranskat)abstract
- Herein, 1,6-Diaminohexane Dihydrochloride (1,6-DD) is introduced into perovskite precursors to fabricate the inverted planar perovskite solar cells. By regulating the concentration of 1,6-DD additive, the average power conversion efficiency (PCE) of perovskite solar cells is enhanced by 20%. The champion device achieves a relatively high PCE of 17% and an excellent fill factor of 80.1%. The PCE of the large-area (1 cm(2)) device also reaches to 13.68%. After exposure to the air for 16 days, the device with 1,6-DD additive still retains above 90% of the initial efficiency, exhibiting good stability. We demonstrate that a small amount of 1,6-DD affects the crystallization dynamic, yielding ideal perovskite film with enhanced crystallinity and enlarged grain size. The two terminal -NH3+ groups passivates the vacancy defects at the perovskite crystal surface, suppressing charge recombination and facilitating charge transportation effectively. Meanwhile, adjacent crystal surfaces are linked through the hexane alkyl chain of 1,6-DD molecule, which enhances the interaction between perovskite grains and anchors the microstructure of perovskite to some degree. Hydrophobic hexane alkyl chains also increase the moisture resistance of perovskite film. Thus, an easy and effective way is provided for fabricating efficient and stable perovskite solar cells.
|
|
